Findings seen at five, 10, and 15 years following surgery versus nonsurgical, matched controls
MONDAY, June 17, 2024 (HealthDay News) — Bariatric surgery significantly decreases the conversion from prediabetes to type 2 diabetes, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.
John Nguyen-Lee, M.D., from the Geisinger Medical Center in Danville, Pennsylvania, and colleagues evaluated the conversion from prediabetes to type 2 diabetes following bariatric surgery versus the conversion rate seen in a nonsurgical cohort. The analysis included 1,326 bariatric cases with prediabetes and propensity-matched nonsurgical controls from a primary care cohort.
The researchers found that the diabetes conversion rate at five, 10, and 15 years postoperatively was 1.8, 3.3, and 6.7 percent, respectively. In matched nonsurgical controls, the diabetes conversion rate was significantly higher at all time points (31.1, 51.4, and 68.7 percent, respectively; hazard ratio, 19.8). Compared with Roux-en-Y gastric bypass, individuals undergoing sleeve gastrectomy were more likely to convert to type 2 diabetes (hazard ratio, 4.01).
“This is the first study to analyze the long-term impact of metabolic and bariatric surgery on the potential progression of prediabetes and the impact is significant and durable,” coauthor David Parker, M.D., also from the Geisinger Medical Center, said in a statement. “It demonstrates that metabolic surgery is as much a treatment as it is a prevention for diabetes.”
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Most Metabolic and Bariatric Surgery Candidates Meet Criteria for Clinical Obesity
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs